<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p252" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_252{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_252{left:306px;bottom:30px;}
#t3_252{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_252{left:346px;bottom:30px;}
#t5_252{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_252{left:517px;bottom:30px;}
#t7_252{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_252{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_252{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_252{left:1105px;bottom:27px;letter-spacing:0.25px;}
#tb_252{left:35px;bottom:777px;letter-spacing:0.13px;word-spacing:0.06px;}
#tc_252{left:35px;bottom:759px;letter-spacing:-0.01px;word-spacing:0.19px;}
#td_252{left:35px;bottom:739px;letter-spacing:0.03px;word-spacing:-0.84px;}
#te_252{left:35px;bottom:720px;letter-spacing:0.06px;word-spacing:0.12px;}
#tf_252{left:35px;bottom:700px;letter-spacing:0.16px;}
#tg_252{left:409px;bottom:700px;}
#th_252{left:35px;bottom:665px;letter-spacing:-0.11px;word-spacing:0.29px;}
#ti_252{left:35px;bottom:645px;letter-spacing:0.06px;word-spacing:0.12px;}
#tj_252{left:35px;bottom:625px;letter-spacing:0.07px;word-spacing:0.12px;}
#tk_252{left:35px;bottom:606px;letter-spacing:0.16px;}
#tl_252{left:405px;bottom:606px;}
#tm_252{left:35px;bottom:570px;letter-spacing:0.08px;word-spacing:0.11px;}
#tn_252{left:35px;bottom:551px;letter-spacing:0.13px;word-spacing:0.06px;}
#to_252{left:35px;bottom:531px;letter-spacing:0.09px;word-spacing:0.09px;}
#tp_252{left:35px;bottom:512px;letter-spacing:0.16px;}
#tq_252{left:405px;bottom:512px;}
#tr_252{left:35px;bottom:476px;letter-spacing:0.09px;word-spacing:-0.47px;}
#ts_252{left:35px;bottom:457px;letter-spacing:0.09px;word-spacing:0.1px;}
#tt_252{left:35px;bottom:437px;letter-spacing:0.09px;word-spacing:0.09px;}
#tu_252{left:35px;bottom:418px;letter-spacing:0.16px;}
#tv_252{left:405px;bottom:418px;}
#tw_252{left:35px;bottom:382px;letter-spacing:0.08px;word-spacing:0.1px;}
#tx_252{left:35px;bottom:363px;letter-spacing:0.08px;word-spacing:0.1px;}
#ty_252{left:35px;bottom:343px;letter-spacing:0.15px;word-spacing:0.04px;}
#tz_252{left:35px;bottom:324px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t10_252{left:132px;bottom:324px;letter-spacing:0.16px;}
#t11_252{left:501px;bottom:324px;}
#t12_252{left:35px;bottom:288px;letter-spacing:0.1px;word-spacing:0.09px;}
#t13_252{left:35px;bottom:269px;letter-spacing:0.09px;word-spacing:0.1px;}
#t14_252{left:35px;bottom:249px;letter-spacing:0.11px;word-spacing:0.08px;}
#t15_252{left:35px;bottom:229px;letter-spacing:0.08px;word-spacing:0.1px;}
#t16_252{left:35px;bottom:210px;letter-spacing:0.16px;}
#t17_252{left:405px;bottom:210px;}
#t18_252{left:35px;bottom:174px;letter-spacing:0.01px;word-spacing:0.18px;}
#t19_252{left:35px;bottom:155px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1a_252{left:35px;bottom:135px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1b_252{left:35px;bottom:116px;letter-spacing:0.16px;}
#t1c_252{left:405px;bottom:116px;}
#t1d_252{left:35px;bottom:80px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1e_252{left:35px;bottom:61px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1f_252{left:618px;bottom:777px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t1g_252{left:618px;bottom:759px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1h_252{left:618px;bottom:739px;letter-spacing:0.16px;}
#t1i_252{left:988px;bottom:739px;}
#t1j_252{left:618px;bottom:702px;letter-spacing:-0.02px;word-spacing:0.2px;}
#t1k_252{left:618px;bottom:683px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1l_252{left:618px;bottom:665px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1m_252{left:618px;bottom:645px;letter-spacing:-0.38px;}
#t1n_252{left:642px;bottom:645px;letter-spacing:0.16px;}
#t1o_252{left:1011px;bottom:645px;}
#t1p_252{left:618px;bottom:608px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1q_252{left:618px;bottom:589px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1r_252{left:618px;bottom:570px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1s_252{left:618px;bottom:551px;letter-spacing:0.16px;}
#t1t_252{left:988px;bottom:551px;}
#t1u_252{left:618px;bottom:514px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1v_252{left:618px;bottom:495px;letter-spacing:0.03px;word-spacing:-0.94px;}
#t1w_252{left:618px;bottom:476px;letter-spacing:0.13px;word-spacing:-0.44px;}
#t1x_252{left:618px;bottom:457px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t1y_252{left:715px;bottom:457px;letter-spacing:0.16px;}
#t1z_252{left:1084px;bottom:457px;}
#t20_252{left:618px;bottom:420px;letter-spacing:0.11px;word-spacing:0.08px;}
#t21_252{left:618px;bottom:401px;letter-spacing:0.03px;word-spacing:0.16px;}
#t22_252{left:618px;bottom:382px;letter-spacing:0.13px;word-spacing:0.06px;}
#t23_252{left:618px;bottom:363px;letter-spacing:0.08px;word-spacing:0.1px;}
#t24_252{left:618px;bottom:343px;letter-spacing:0.16px;}
#t25_252{left:988px;bottom:343px;}
#t26_252{left:618px;bottom:306px;word-spacing:0.19px;}
#t27_252{left:618px;bottom:288px;letter-spacing:0.11px;word-spacing:0.08px;}
#t28_252{left:618px;bottom:269px;letter-spacing:0.08px;word-spacing:0.1px;}
#t29_252{left:618px;bottom:249px;letter-spacing:0.17px;word-spacing:-0.6px;}
#t2a_252{left:618px;bottom:229px;letter-spacing:-0.07px;word-spacing:0.25px;}
#t2b_252{left:763px;bottom:229px;letter-spacing:0.16px;}
#t2c_252{left:1132px;bottom:229px;}
#t2d_252{left:618px;bottom:194px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t2e_252{left:618px;bottom:174px;letter-spacing:0.1px;word-spacing:-0.16px;}
#t2f_252{left:618px;bottom:155px;letter-spacing:0.04px;word-spacing:-0.16px;}
#t2g_252{left:618px;bottom:135px;letter-spacing:-0.38px;}
#t2h_252{left:642px;bottom:135px;letter-spacing:0.16px;}
#t2i_252{left:1011px;bottom:135px;}
#t2j_252{left:618px;bottom:100px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2k_252{left:618px;bottom:80px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2l_252{left:618px;bottom:61px;letter-spacing:0.03px;word-spacing:0.16px;}
#t2m_252{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_252{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_252{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_252{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_252{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_252{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_252{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_252{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts252" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg252Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg252" style="-webkit-user-select: none;"><object width="1210" height="935" data="252/252.svg" type="image/svg+xml" id="pdf252" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_252" class="t s0_252">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_252" class="t s1_252">© </span>
<span id="t3_252" class="t s0_252">(NCCN </span>
<span id="t4_252" class="t s1_252">© </span>
<span id="t5_252" class="t s0_252">), All rights reserved. NCCN Guidelines </span>
<span id="t6_252" class="t s1_252">® </span>
<span id="t7_252" class="t s0_252">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_252" class="t s2_252">NCCN Guidelines Version 4.2024 </span>
<span id="t9_252" class="t s2_252">Head and Neck Cancers </span>
<span id="ta_252" class="t s3_252">MS-111 </span>
<span id="tb_252" class="t s4_252">708. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and </span>
<span id="tc_252" class="t s4_252">prostatic specific markers in salivary duct carcinoma: an </span>
<span id="td_252" class="t s4_252">immunohistochemical analysis of 13 cases and review of the literature. Am </span>
<span id="te_252" class="t s4_252">J Surg Pathol 2000;24:579-586. Available at: </span>
<span id="tf_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/10757407/</span><span id="tg_252" class="t s4_252">. </span>
<span id="th_252" class="t s4_252">709. Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: an </span>
<span id="ti_252" class="t s4_252">aggressive salivary gland malignancy with opportunities for targeted </span>
<span id="tj_252" class="t s4_252">therapy. Oral Oncol 2017;74:40-48. Available at: </span>
<span id="tk_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/29103750</span><span id="tl_252" class="t s4_252">. </span>
<span id="tm_252" class="t s4_252">710. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in </span>
<span id="tn_252" class="t s4_252">TRK fusion-positive cancers in adults and children. N Engl J Med </span>
<span id="to_252" class="t s4_252">2018;378:731-739. Available at: </span>
<span id="tp_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/29466156</span><span id="tq_252" class="t s4_252">. </span>
<span id="tr_252" class="t s4_252">711. Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with </span>
<span id="ts_252" class="t s4_252">solid tumours: a multi-centre, open-label, phase I dose-escalation study. </span>
<span id="tt_252" class="t s4_252">Ann Oncol 2019;30:325-331. Available at: </span>
<span id="tu_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/30624546</span><span id="tv_252" class="t s4_252">. </span>
<span id="tw_252" class="t s4_252">712. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with </span>
<span id="tx_252" class="t s4_252">advanced or metastatic NTRK fusion-positive solid tumours: integrated </span>
<span id="ty_252" class="t s4_252">analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-282. </span>
<span id="tz_252" class="t s4_252">Available at: </span><span id="t10_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/31838007</span><span id="t11_252" class="t s4_252">. </span>
<span id="t12_252" class="t s4_252">713. Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy </span>
<span id="t13_252" class="t s4_252">for androgen receptor-positive advanced salivary duct carcinoma: a </span>
<span id="t14_252" class="t s4_252">nationwide case series of 35 patients in the Netherlands. Head Neck </span>
<span id="t15_252" class="t s4_252">2018;40:605-613. Available at: </span>
<span id="t16_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/29272069</span><span id="t17_252" class="t s4_252">. </span>
<span id="t18_252" class="t s4_252">714. Yamamoto N, Minami S, Fujii M. Clinicopathologic study of salivary </span>
<span id="t19_252" class="t s4_252">duct carcinoma and the efficacy of androgen deprivation therapy. Am J </span>
<span id="t1a_252" class="t s4_252">Otolaryngol 2014;35:731-735. Available at: </span>
<span id="t1b_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/25087467</span><span id="t1c_252" class="t s4_252">. </span>
<span id="t1d_252" class="t s4_252">715. Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study </span>
<span id="t1e_252" class="t s4_252">of combined androgen blockade in patients with androgen receptor- </span>
<span id="t1f_252" class="t s4_252">positive metastatic or locally advanced unresectable salivary gland </span>
<span id="t1g_252" class="t s4_252">carcinoma. Ann Oncol 2018;29:979-984. Available at: </span>
<span id="t1h_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/29211833</span><span id="t1i_252" class="t s4_252">. </span>
<span id="t1j_252" class="t s4_252">716. Locati LD, Cavalieri S, Bergamini C, et al. Abiraterone acetate in </span>
<span id="t1k_252" class="t s4_252">patients with castration-resistant, androgen receptor-expressing salivary </span>
<span id="t1l_252" class="t s4_252">gland cancer: a phase II trial. J Clin Oncol 2021;39:4061-4068. Available </span>
<span id="t1m_252" class="t s4_252">at: </span><span id="t1n_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/34597119</span><span id="t1o_252" class="t s4_252">. </span>
<span id="t1p_252" class="t s4_252">717. Gilbert MR, Sharma A, Schmitt NC, et al. A 20-year review of 75 </span>
<span id="t1q_252" class="t s4_252">cases of salivary duct carcinoma. JAMA Otolaryngol Head Neck Surg </span>
<span id="t1r_252" class="t s4_252">2016;142:489-495. Available at: </span>
<span id="t1s_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/26939990</span><span id="t1t_252" class="t s4_252">. </span>
<span id="t1u_252" class="t s4_252">718. Thorpe LM, Schrock AB, Erlich RL, et al. Significant and durable </span>
<span id="t1v_252" class="t s4_252">clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary </span>
<span id="t1w_252" class="t s4_252">gland cancer and a review of the literature. Head Neck 2017;39:E40-e44. </span>
<span id="t1x_252" class="t s4_252">Available at: </span><span id="t1y_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/28006087</span><span id="t1z_252" class="t s4_252">. </span>
<span id="t20_252" class="t s4_252">719. Correa TS, Matos GDR, Segura M, Dos Anjos CH. Second-line </span>
<span id="t21_252" class="t s4_252">treatment of HER2-positive salivary gland tumor: ado-trastuzumab </span>
<span id="t22_252" class="t s4_252">emtansine (T-DM1) after progression on trastuzumab. Case Rep Oncol </span>
<span id="t23_252" class="t s4_252">2018;11:252-257. Available at: </span>
<span id="t24_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/29867432</span><span id="t25_252" class="t s4_252">. </span>
<span id="t26_252" class="t s4_252">720. Jhaveri KL, Wang XV, Makker V, et al. Ado-trastuzumab emtansine </span>
<span id="t27_252" class="t s4_252">(T-DM1) in patients with HER2-amplified tumors excluding breast and </span>
<span id="t28_252" class="t s4_252">gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from </span>
<span id="t29_252" class="t s4_252">the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 2019;30:1821- </span>
<span id="t2a_252" class="t s4_252">1830. Available at: </span><span id="t2b_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/31504139</span><span id="t2c_252" class="t s4_252">. </span>
<span id="t2d_252" class="t s4_252">721. Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab </span>
<span id="t2e_252" class="t s4_252">and docetaxel in patients with human epidermal growth factor receptor 2- </span>
<span id="t2f_252" class="t s4_252">positive salivary duct carcinoma. J Clin Oncol 2019;37:125-134. Available </span>
<span id="t2g_252" class="t s4_252">at: </span><span id="t2h_252" class="t s5_252">https://www.ncbi.nlm.nih.gov/pubmed/30452336</span><span id="t2i_252" class="t s4_252">. </span>
<span id="t2j_252" class="t s4_252">722. Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for </span>
<span id="t2k_252" class="t s4_252">advanced salivary gland carcinoma based on molecular profiling: results </span>
<span id="t2l_252" class="t s4_252">from MyPathway, a phase IIa multiple basket study. Ann Oncol </span>
<span id="t2m_252" class="t s6_252">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
